Item 3.02: Unregistered Sales of Equity Securities – The filing reports an unregistered sale of equity securities by Becton Dickinson & Co. Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year – The company made amendments to its articles of incorporation or bylaws, and/or changed its fiscal year. Item 9.01: Financial Statements and Exhibits – The filing includes…

Our analysis rates this filing NEUTRAL. The moderate concern level (4.8/10) reflects a balanced assessment of a large, financially stable company executing a planned strategic transaction. While the Reverse Morris Trust transaction introduces execution risk (severity 5/10), this is a known,…

Concern level: ELEVATED (4.8/10). Key factors: Reverse Morris Trust transaction execution risk (severity 5/10) - complex multi-party deal with regulatory and operational dependencies; failure could disrupt operations and shareholder value; Transaction complexity introduces near-term uncertainty - separation of Biosciences and Diagnostic Solutions business requires successful coordination with…

Notable risk changes: BD filed Certificate of Designation for Series D Junior Participating Redeemable Preferred Stock on January 30, 2026 - structural preparation for RMT transaction with Waters Corporation; Executed exchange agreements with two rabbi trusts (Salary and Bonus Deferral Plan Trust and 1996 Directors' Deferral Plan Trust) on February 2, 2026, exchanging 27.5159 preferred shares for common stock…

The model predicts BDX will underperform the S&P 500 by about 0.0% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.